AIM ImmunoTech converts $1.22M promissory note into 5.07M shares, note satisfied

AIM ImmunoTech Inc.

Converted ~$1,224,341 of Feb 16, 2024 promissory note into 5,065,840 shares at avg $0.24/share.
Promissory note (original principal $3,301,250) fully satisfied as of Sept 3, 2026; no amounts owing.
Exchange shares issued under Section 3(a)(9) exemption; no commission or remuneration paid.
Stockholders approved conversion at July 15, 2026 special meeting per NYSE American rules.
Shares to be free-trading under Rule 144; holding period tacks to Feb 16, 2024 original note date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.